share_log

MicroPort Scientific (HKG:853) Adds HK$550m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 88%

MicroPort Scientific (HKG:853) Adds HK$550m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 88%

微創科技(HKG: 853)在過去7天內市值增加了5.5億港元,儘管三年前的投資者仍下跌了88%
Simply Wall St ·  01/29 17:27

As every investor would know, not every swing hits the sweet spot. But you have a problem if you face massive losses more than once in a while. So consider, for a moment, the misfortune of MicroPort Scientific Corporation (HKG:853) investors who have held the stock for three years as it declined a whopping 88%. That might cause some serious doubts about the merits of the initial decision to buy the stock, to put it mildly. And over the last year the share price fell 75%, so we doubt many shareholders are delighted. Furthermore, it's down 49% in about a quarter. That's not much fun for holders. We really feel for shareholders in this scenario. It's a good reminder of the importance of diversification, and it's worth keeping in mind there's more to life than money, anyway.

正如每個投資者所知道的那樣,並非每一次波動都能達到最佳水平。但是,如果你不止一次地面臨巨額損失,你就會遇到問題。因此,暫時考慮一下微創科學公司(HKG: 853)投資者的不幸,他們持有該股三年,跌幅高達88%。客氣地說,這可能會使人們嚴重懷疑最初購買該股票的決定的優點。在過去的一年中,股價下跌了75%,因此我們懷疑許多股東是否感到高興。此外,它在大約一個季度內下降了49%。對於持有者來說,這沒什麼好玩的。在這種情況下,我們真的對股東有同感。這很好地提醒了多元化的重要性,無論如何,值得記住的是,生活中存在的不僅僅是金錢。

While the stock has risen 5.1% in the past week but long term shareholders are still in the red, let's see what the fundamentals can tell us.

儘管該股在過去一週上漲了5.1%,但長期股東仍處於虧損狀態,但讓我們看看基本面能告訴我們什麼。

View our latest analysis for MicroPort Scientific

查看我們對微創科技的最新分析

MicroPort Scientific wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

MicroPort Scientific在過去十二個月中沒有盈利,我們不太可能看到其股價與每股收益(EPS)之間存在很強的相關性。可以說,收入是我們的下一個最佳選擇。一般而言,沒有利潤的公司預計每年收入將增長,而且速度很快。可以想象,收入的快速增長如果持續下去,通常會帶來利潤的快速增長。

In the last three years, MicroPort Scientific saw its revenue grow by 10% per year, compound. That's a fairly respectable growth rate. So it's hard to believe the share price decline of 24% per year is due to the revenue. More likely, the market was spooked by the cost of that revenue. This is exactly why investors need to diversify - even when a loss making company grows revenue, it can fail to deliver for shareholders.

在過去的三年中,MicroPort Scientific的收入每年增長10%,複合增長。這是一個相當可觀的增長率。因此,很難相信股價每年下跌24%是由於收入造成的。更有可能的是,這筆收入的成本嚇壞了市場。這正是投資者需要分散投資的原因——即使虧損公司增加了收入,也可能無法爲股東帶來收益。

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

您可以在下圖中看到收入和收入隨時間推移而發生的變化(點擊圖表查看確切值)。

earnings-and-revenue-growth
SEHK:853 Earnings and Revenue Growth January 29th 2024
SEHK: 853 2024年1月29日收益和收入增長

This free interactive report on MicroPort Scientific's balance sheet strength is a great place to start, if you want to investigate the stock further.

如果你想進一步調查該股,這份關於MicroPort Scientific資產負債表實力的免費互動報告是一個很好的起點。

A Different Perspective

不同的視角

We regret to report that MicroPort Scientific shareholders are down 75% for the year. Unfortunately, that's worse than the broader market decline of 20%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 3% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 1 warning sign for MicroPort Scientific that you should be aware of.

我們遺憾地報告,微創科學的股東今年下跌了75%。不幸的是,這比整個市場20%的跌幅還要嚴重。但是,可能只是股價受到了更廣泛的市場緊張情緒的影響。如果有很好的機會,可能值得關注基本面。遺憾的是,去年的業績結束了糟糕的表現,股東在五年內每年面臨3%的總虧損。我們意識到羅斯柴爾德男爵曾說過,投資者應該 “在街頭流血時買入”,但我們警告說,投資者應首先確保他們購買的是高質量的企業。我發現將長期股價視爲業務績效的代表非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,我們已經爲 MicroPort Scientific 確定了一個你應該注意的警告信號。

Of course MicroPort Scientific may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

當然,微創科技可能不是最值得購買的股票。因此,您可能希望看到這批免費的成長股。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Hong Kong exchanges.

請注意,本文引用的市場回報反映了目前在香港交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論